Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)

Organization
NCI
Type
NIH
Application or LOI Due Date
05-30-2021
Number
RFA-CA-21-024
Comments
LOI due 5/30/21. Application due 6/30/21.
Brief Description

This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science.

This FOA solicits applications for multidisciplinary Proteogenomic Data Analysis Centers (PGDACs), which will provide data analysis and biological and clinical interpretation of CPTAC data. PGDAC awardees will be expected to develop computational tools for data analysis, data integration and visualization and apply these tools to CPTAC data.

PGDACs will interact with additional CPTAC Centers that include:

  • Proteome Characterization Centers (PCC, to be supported by RFA-CA-21-023; U24), that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically characterized samples. These samples (human biospecimens and preclinical models) will be provided by the NCI; and
  • Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-21-025; U01) that will apply state-of-the-art proteomic and proteogenomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a patient's tumor.